Dana Farber Cancer Institute

The Haley Cremer Foundation proudly supports the advancement of Dr. Mehra Golshan’s breast cancer research at the Dana-Farber Cancer Institute


Dr. Mehra Golshan

Golshan MD, MBA is the incumbent Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology at the Brigham and Women’s Hospital. He is also the Director of the Breast Surgical Oncology Fellowship at the Dana-Farber Cancer Institute / Brigham and Women’s Hospital / Massachusetts General Hospital and an Associate Professor of Surgery at Harvard Medical School. He chairs the Dana Farber / Brigham and Women’s Cancer Center: Committee for the American College of Surgeon’s Commission on Cancer and serves as the Cancer Liaison Physician as well.

Dr. Golshan received his medical degree from Case Western Reserve University School of Medicine. He completed a residency in general surgery at Rush-Presbyterian-Saint Luke’s Medical Center and a breast surgical oncology fellowship at Northwestern Memorial Hospital. He is board certified in surgery. He runs a busy clinical practice focused exclusively on breast surgical oncology, a robust clinical trials group and completed his MBA at the MIT Sloan School of Management in May of 2019. He is the author of over 115 peer-reviewed publications and recipient of funding from the Breast Cancer Research Foundation and the National Institutes of Health.

Dr. Golshan focuses his clinical research on minimizing the extent of surgery required for women with breast cancer through the use of neoadjuvant therapies and novel intra-operative imaging and margin analysis techniques. He is studying the use of intra-operative diagnostic biomarkers and tools in Brigham and Women’s Advanced Multimodality Image Guided Operative (AMIGO) Suite to determine if they can identify and remove residual tumor with the aim of improving patient outcomes and reducing re-excision rates. Dr. Golshan is also a leading researcher on tailoring the extent of surgery and therapy for women with early-stage breast cancer. Dr. Golshan has been consistently named one of America’s Top Doctors by Castle Connolly and named a top surgeon in Boston Magazine.

Triple-negative Breast Cancer Studies
BrighTNess is a multi-phase international trial looking at breast conservation for women with triple-negative breast cancer (TNBC) who are treated with neoadjuvant systemic therapy (NST)—a type of chemotherapy used in patients to make their inoperable breast cancers operable by shrinking the tumors. TNBC accounts for nearly 15 percent of all breast cancers, and the only treatment currently approved for women with early-stage TNBC is chemotherapy. In phase III of the BrighTNess trial, Dr. Golshan and his team assessed the results after patients underwent either lumpectomy or mastectomy after NST and found that NST increased eligibility for women with TNBC to undergo lumpectomy—the less radical breast surgery. Dr. Golshan and his team are now tracking outcomes of these patients for recurrence, death, and survival rates. Dr. Golshan and his team are also currently reviewing MRI data to determine if it can predict a TNBC patient’s response to drug therapy and help their surgeon make decisions regarding treatment. Results of this trial were presented at the worlds largest cancer meeting ASCO and surgical results were presented at the European Society of Surgical Oncology. Efforts are now underway to better understand patient decision making on lumpectomy versus mastectomy and if the more robust responses we are seeing with better drug therapy are appropriately being reflected with less radical surgical procedures. Your support will help us with surveying techniques and tools to better educate patients here in the United States and around the world.

Clear Margins Studies and Better Breast MRI
Dr. Golshan and his team continue to participate in a unique trial designed to achieve clear margins—the boundary of healthy, cancer-free tissue that should remain after the surgical removal of a tumor. Obtaining clear margins during surgery can lead to improved long-term prognosis for patients, reduce the delay in receipt of adjuvant therapy, and decrease infection rates. To determine the best surgical approaches for achieving clear margins, Dr. Golshan performs surgeries in BWH’s AMIGO suite—a state-of-the-art medical and surgical research environment that houses a complete array of advanced imaging equipment and interventional surgical systems, including magnetic resonance imaging (MRI), positron emission tomography (PET) scanners, computerized tomography (CT) scanners, mass spectrometry devices, and other imaging modalities. Using the AMIGO suite, Dr. Golshan can accurately view tumor margins in real time during surgery, increasing his ability to obtain clear margins in a single procedure.

Because of Dr. Golshan’s success using the AMIGO suite during this clear margins trial, now all breast cancer patients at the Brigham who are receiving chemotherapy on trial prior to surgery are also receiving the prone/supine MRI so that surgeons can see how the tumor responded and changed. With your support, Dr. Golshan successfully took what he learned while working in the AMIGO suite and helped apply it to treatment for all breast cancer patients at the Brigham. This new step in patient workflow is now being implemented at other hospitals in the country, and Dr. Golshan hopes that lessons learned in the AMIGO suite will continue to be applied on a larger scale.